A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Trial Profile

A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2013

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Pharmacokinetics
  • Sponsors Peplin
  • Most Recent Events

    • 12 Mar 2013 New trial record
    • 05 Mar 2013 Tolerability results presented at the 71st Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top